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Abstract
Background: External cephalic version (ECV) is recommended by the American College of Obstetricians and
Gynecologists to convert a breech fetus to vertex position and reduce the need for cesarean delivery. The goal of
this study was to determine the incremental cost-effectiveness ratio, from society’s perspective, of ECV compared
to scheduled cesarean for term breech presentation.
Methods: A computer-based decision model (TreeAge Pro 2008, Tree Age Software, Inc.) was developed for a
hypothetical base case parturient presenting with a term singleton breech fetus with no contraindications for
vaginal delivery. The model incorporated actual hospital costs (e.g., $8,023 for cesarean and $5,581 for vaginal
delivery), utilities to quantify health-related quality of life, and probabilities based on analysis of published literature
of successful ECV trial, spontaneous reversion, mode of delivery, and need for unanticipated emergency cesarean
delivery. The primary endpoint was the incremental cost-effectiveness ratio in dollars per quality-adjusted year of
life gained. A threshold of $50,000 per quality-adjusted life-years (QALY) was used to determine cost-effectiveness.
Results: The incremental cost-effectiveness of ECV, assuming a baseline 58% success rate, equaled $7,900/QALY. If
the estimated probability of successful ECV is less than 32%, then ECV costs more to society and has poorer QALYs
for the patient. However, as the probability of successful ECV was between 32% and 63%, ECV cost more than
cesarean delivery but with greater associated QALY such that the cost-effectiveness ratio was less than $50,000/
QALY. If the probability of successful ECV was greater than 63%, the computer modeling indicated that a trial of
ECV is less costly and with better QALYs than a scheduled cesarean. The cost-effectiveness of a trial of ECV is most
sensitive to its probability of success, and not to the probabilities of a cesarean after ECV, spontaneous reversion to
breech, successful second ECV trial, or adverse outcome from emergency cesarean.
Conclusions: From society’s perspective, ECV trial is cost-effective when compared to a scheduled cesarean for
breech presentation provided the probability of successful ECV is > 32%. Improved algorithms are needed to more
precisely estimate the likelihood that a patient will have a successful ECV.
Background
Breech presentation at term occurs in 3-4% of pregnan-
cies and is managed with elective cesarean, assisted vagi-
nal delivery, or external cephalic version (ECV) [1,2].
Approximately 87% of breech presentations in the Uni-
ted States resulted in cesarean delivery [3], a significant
increase from previous years [4,5]. Breech presentation
is the third most common indication for cesarean and
in some hospitals breech presentations are managed
exclusively by cesarean delivery [6,7]. This may in part
be due to the Term Breech Trial in 2000 that confirmed
that breech presentations delivered by cesareans resulted
in less neonatal mortality and short-term morbidity
compared to vaginal breech delivery [8]. Maternal com-
plications were also found to be similar for cesarean and
vaginal delivery in the short [9] and long term [10,11].
Practice guidelines from the American College of
Obstetrics and Gynecologists (ACOG) in 2006 recom-
mend that decisions regarding the mode of delivery for
breech presentation are dependent on the health care
provider’s experience. ACOG also suggests that cesarean
deliveries are preferred over vaginal breech deliveries
[12]. The desire to decrease the number of cesareans
has renewed interest in ECV [13,14]. In fact, ACOG
recommends ECV to lower the number of breech
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presentations [12,15]. ECV is indicated for women pre-
senting with a confirmed singleton breech fetus at ≥ 36
completed weeks with no contraindications for vaginal
delivery [16,17].
Quantifying the cost and effectiveness of ECV for
breech presentation compared to scheduled cesarean is
complicated because ECV does not always result in a
cephalic presentation and subsequent vaginal delivery.
While the probability of success in ECV is approxi-
mately 58% [18], the fetus may spontaneously revert
back to breech before delivery [19]. In addition, vertex
presentation at term does not necessarily translate to a
vaginal delivery and a cesarean may still be performed
for other reasons [20]. An unsuccessful ECV may war-
rant a second trial of ECV and potential adverse events
with each trial, such as emergent caesarean section [21].
Patient preferences need to be factored into the
decision.
Cost-effectiveness analysis produces a ratio. The
numerator takes into consideration the additional costs
that one intervention imposes over another. The
denominator considers the incremental improvement in
health-related quality of life calculated as quality-
adjusted life-years (QALY). The goal of this study was
to determine the incremental cost-effectiveness ratio,
from society’s perspective, of ECV compared to directly
scheduling a cesarean delivery for term breech presenta-
tion. Our base case focuses on a parturient presenting
with an ultrasound confirmed singleton breech fetus at
≥ 36 completed weeks gestation, with no contraindica-
tions for vaginal delivery. The base case represents a
baseline scenario for the initial analysis before any of




We developed a computer-based decision tree model
using TreeAge Pro 2008 (Tree Age Software, Inc., Wil-
liamstown, MA) to evaluate the incremental cost-effec-
tiveness of ECV (Figure 1). The primary outcome of the
analysis was the incremental cost-effectiveness ratio, in
2007 U.S. Dollars per QALY. A societal perspective, was
assumed as is commonly done to account for society
having given up the opportunity to use those resources
for some other purpose.
Also as commonly accepted, a threshold of $50,000
per QALY was used to determine cost-effectiveness.
The time horizon captured in the study was 12-weeks
after delivery which allowed for 6 weeks of recovery for
vaginal delivery and 8 weeks for Cesarean. The 12-week
time frame also allowed for maternal and neonatal
adverse events and hospitalization times during delivery
and recovery to be incorporated.
The main uncertainties are whether the ECV is suc-
cessful in maneuvering the fetus to the vertex position,
unsuccessful, or unsuccessful with the need for an emer-
gency cesarean at the time of ECV. Following a success-
ful ECV, further uncertainty exists between the fetus
remaining vertex or spontaneously reverting back to
breech. Following an unsuccessful, uncomplicated ECV,
an elective cesarean delivery can be chosen or a second
trial of ECV can be scheduled at another time. We
modeled a different probability of success for the second
ECV trial. Three modes of delivery were possible includ-
ing, vaginal delivery, cesarean delivery or an emergency
cesarean delivery. In addition, an emergency cesarean
delivery may result in an adverse maternal or neonatal
outcome necessitating ICU or NICU hospitalization
Model Probabilities
We systematically reviewed the literature to determine
the decision model probabilities for successful ECV on
the first and second attempts, spontaneous reversion,
mode of delivery and need for unanticipated emergency
cesarean delivery (Table 1). We searched Medline,
Cochrane and Up-to-Date for English-language peer-
reviewed literature published between 1985 and 2008.
Key words used in our search were: external cephalic
version, breech, cesarean delivery, spontaneous rever-
sion, and emergency cesarean section. We supplemented
the search with a manual review of references from the
retrieved articles.
Where possible, probabilities were extracted from
meta-analyses. If data were not available from a meta-
analysis, probabilities were estimated by calculating the
mean probability across the literature found in our
review. This method allowed for studies to be weighed
appropriately according to number of subjects. For
example, the probability of successful ECV on the sec-
ond trial used in our base case analysis was calculated
to be 51%. This value was derived from three studies
reporting repeat ECV success rates of 39.7% (27/68)
[22], 71% (77/108) [23], and 17% (6/36) [24], where the
numerators represent successful cases and denominators
represent total number of subjects in their respective
study. The ranges for our sensitivity analysis were
derived from the upper and lower probability values
identified in the literature review. In the example of the
probability of successful second trial of ECV, the range
used was 17-71%. Sensitivity analysis was useful in this
case to determine the relative impact of changing prob-
abilities on the outcome of our model, especially where
the ranges reported in the literature were large.
Determining Effectiveness
The primary measure of effectiveness was health-related
quality of life calculated as QALY, which include a
length of time component (e.g., 1 year) and a quality of
life component (i.e., utility). The effectiveness measure
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was dependent on the assigned quality of life compo-
nent (utility), the duration of the assigned quality of life
and the total length of time captured in the model (12
weeks after delivery). Health utility is the numerical
valuation of one’s quality of life on a linear scale from
0.00 (death) to 1.00 (perfect health). For example, one
QALY for an individual in perfect health (with a utility
of 1.0) for 1 year is considered equivalent to 2 years in a
health state with a utility of 0.5 (as might occur with a
disability). Maternal health outcomes and fetal health
outcomes were weighed equally.
Table 2 describes the utilities assigned to each of the
maternal and neonatal health states. Four health states
were used in the model including, perfect health, well
health after vaginal delivery, well health after cesarean
delivery and health during an adverse outcome due to
an emergency cesarean. Maternal health states were
independent of neonatal health states. Health states
were estimated through observation and simulation of a
mother and child experiencing each of the four health
states used in the model.
Maternal health quality of life was calculated with
cesarean delivery as requiring a longer recovery time
when compared to vaginal delivery. Direct measurement
of utilities in patients recovering after delivery has not
been performed. In such situations, the U.S. Panel on
Cost-Effectiveness in Health and Medicine recommend
the use of scale of valuations of states such as the Euro-
Qol© scale to be used [25]. For example, patients in the
EuroQol© EQ-5D scale are classified into one of five dif-
ferent health states (mobility, self-care, usual activity,
pain, mood) [26]. Each state is scored from 1 (normal)
to 3 (the most impaired). For example, a mobility score
of “1” indicates “no problems in walking about,” while a
“3” is “confined to bed.” The scores for the five states
can be assigned a utility valuation from the general pub-
lic. For example, a EuroQol© mobility [3], self-care [3],
usual activity [3], pain [2], mood [1] signifies a utility of
0.08. In contrast, EuroQol© mobility [1], self-care [1],
usual activity [2], pain [1], mood [2] signifies a utility of
0.65.
The expected quality of life for a vaginal delivery was
based on the first 7 days at a utility of 0.50 and the
remainder of the 6 weeks for recovery at a utility of
0.77. We assumed that the mother would subsequently
return to perfect health at a utility of 1.00. Therefore,
the mean utility following vaginal delivery was 0.86.
The expected quality of life for a cesarean delivery was
based on the first 21 days at a utility of 0.41 and the
remainder of the 8 weeks for recovery at a utility of
Figure 1 ECV Decision Tree Model*.
Table 1 Estimated Probability (%) of Outcomes Utilized in Cost-Effectiveness Model
Base Case Probability (Range) References
Successful ECV Procedure
First Trial 58% (35-86%) [18]
Second Trial* 51% (17-71%) [22-24]
Consequence of ECV
Fetus remains Vertex - -
Cephalic Delivery with Successful ECV - -
Cesarean After Successful ECV 27.60% (8.5-30%) [7,43,44]
Fetus Spontaneously Reverts to Breech * 6% (3-10%) [19,45-47]
Emergency Cesarean Needed at time of ECV 0.35% (0-1%) [21,48]
Adverse Outcome from Emergency Cesarean † 1% (0-1%)
* Likelihood used in model base case is the weighted average of studies reviewed where the numerator and denominator across multiple studies were summed.
†Ranges of 0-1% were included in the sensitivity analysis even though no literature referenced these ranges in order to see the effect of both rare but expensive
adverse events.
Tan et al. BMC Pregnancy and Childbirth 2010, 10:3
http://www.biomedcentral.com/1471-2393/10/3
Page 3 of 8
0.77. We made the assumption that the mother would
subsequently return to perfect health. Therefore, the
mean utility following cesarean delivery was 0.78. The
expected duration of health states during the recovery
phase varied based on whether the mother and child
were recovering from a vaginal or cesarean delivery.
The recovery times for vaginal and cesarean delivery
reflected the different standard time periods the law
and society provides a mother to take off from work
for recovery. Similar derivations to determine QALYs
associated with each health state for the year following
delivery were conducted for the neonate [27].
In the event of an adverse outcome following an emer-
gency cesarean we assumed a 2-day hospital stay in the
ICU or NICU was required at a mean utility of 0.76 and
0.75, respectively. The mean ICU or NICU utility for the
mother and child was derived from an assumed 2-day ICU
or NICU stay at a utility of 0.17 and 0.20 respectively, fol-
lowed by utility of 0.60 for the subsequent 2 weeks post-
delivery and a utility of 0.77 for the following 8 weeks
until return to perfect health. We did not have to extrapo-
late QALY calculations beyond 12 weeks and therefore did
not discount the utilities to adjust for future effects.
Determining Costs
The cost of a medical service from society’s point of
view is the total net cost to all the different components
of society. Direct hospital costs were included in the
numerator of the cost-effectiveness ratio whereas indir-
ect costs (or productivity costs) caused by morbidity or
mortality were incorporated by the effectiveness mea-
sure, QALY, in the denominator. The use of costs and
not charges as they appear on a patient’s hospital bill is
appropriate for our economic analyses because charges
are known not to capture the actual economic conse-
quences of an event. The use of costs from the perspec-
tive of society is further in accordance with
recommendations by the U.S. Panel on Cost-Effective-
ness in Health and Medicine [25].
Table 3 presents the costs of ECV, vaginal delivery,
elective cesarean delivery and an emergency cesarean
delivery. Each of the total costs were composed of the
hospital cost, the professional cost of the obstetrician
and anesthesiologists service, and the cost of the
mother’s time from a missed day of work according to
the U.S. Census Bureau’s 2003 median income for a
full-time, year-round, female worker. We assumed the
cost of a mother’s missed day of work as an estimate of
the opportunity cost of a mother participating in a pro-
cedure or hospital stay. Expected duration of procedure
and length of stay were obtained from the US Depart-
ment of Health and Human Services Healthcare Cost
and Utilization Project data [28]. The calculated values
are similar to previous studies [27,29,30].
Table 4 presents the derivation of the cost estimate
for ECV. The cost estimates of ECV were determined by
summing the cost of the individual components for the
procedure. Physician professional costs were determined
using the Current Procedural Terminology (CPT) codes
reimbursed at the 2007 Medicare rate without geo-
graphic adjustment, such that, for example, the cost of
the obstetrician’s service for CPT 59412 (External
Cephalic Version) equals $114. Similarly, calculations of
cost of physician services were also obtained for CPT
59590 (routine obstetric care including antepartum care,
cesarean delivery, and postpartum care). The cost of the
anesthesiologist’s service during a cesarean for example
was also based on 2007 Medicare reimbursement rate of
$20/unit. Using Medicare rates to estimate costs of phy-
sician services is the most common method used in
health services research [27,28,30,31]. The cost of a
labor nurse for the duration of the procedure antici-
pated to last 1.5 hour was estimated at $81.
The cost of an adverse outcome due to an emergency
cesarean delivery was also included in the analysis to cap-
ture the cost of a rare but highly expensive event, from a
financial and quality of life perspective. The cost of
Table 2 Utility Analysis Using Quality Adjusted Life Years (QALYs) for 12 Weeks
Mean Utility Expected Mean Duration* QALY
Maternal Health State
Perfect Health (Post-Recovery Phase) 1 - 1
Well Health after Vaginal Delivery 0.86 12 Weeks 0.97
Well Health after Cesarean Delivery 0.78 12 Weeks 0.95
Adverse Outcome Following Emergency Cearean (2-Day Hospitalization) 0.76 12 Weeks 0.93
Neonatal Health State
Perfect Health (Post-Recovery Phase) 1 - 1
Well Health after Vaginal Delivery 1.00 12 weeks 1.00
Well Health after Cesarean Delivery 1.00 12 weeks 1.00
Adverse Outcome Following Emergency Cesarean (2-Day Hospitalization) 0.58 12 Weeks 0.90
*Duration of perfect health is dependent on 12 weeks minus the time spent in recovery
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complications due to emergency cesarean delivery was
estimated as maternal hospitalization of an additional
$1,155 per additional ward day. The cost of complica-
tions due to emergency cesarean delivery for the neonate
was assumed to cost $285 for a mild case of perinatal
morbidity (2 hours of Neonatal intensive care unit moni-
toring + Perinatologist). Costs associated with maternal
and neonatal morbidities assume successful treatment
without subsequent complications. All costs were
reported in 2007 United States Dollars. Future costs were
discounted at 3% per annum in the base case scenario.
Sensitivity Analyses
Sensitivity analyses were conducted to test a range (e.g.,
from low probability to the high probability of a particu-
lar event occurring) of values and determine their
impact on the model. Ranges of probabilities tested can
be found in Table 1. We conducted one-way and multi-
way sensitivity analyses on both probabilities and costs
across a range of values identified from the literature
and cost calculations.
Results
The estimated baseline cost for ECV equaled $1,024
(Table 4). Assuming a 58% chance of successful ECV,
ECV resulted in an incremental cost-effectiveness ratio
of $7,900/QALY in our base case when compared to
scheduled cesarean (Table 5). This ratio is less than the
commonly accepted threshold of $50,000 per QALY for
an intervention. Therefore, ECV with a 58% likelihood
of success can be considered cost-effective. Attempting
a second ECV if the first failed was not cost-effective.
We found the decision model was only sensitive to the
probability of successful ECV on the first trial. If the
expected probability of successful ECV is less than 32%,
then ECV costs more to society and has poorer QALYs
for the patient. When the probability of successful ECV
was between 32% and 63%, trial of ECV was cost-effec-
tive, meaning that the expected costs were higher than
with scheduled cesarean delivery but with better out-
comes. However, if the probability of successful ECV
was greater than 63%, trial of ECV had less expected
costs than cesarean delivery with better clinical
outcomes.
The probability of conducting cesarean after successful
ECV (range 8.5-30%), spontaneous reversion to breech
(range 3-10%), probability of successful second trial of
ECV (range 17-71%), emergency cesarean (range 0-1%)
and adverse outcome from emergency cesarean (range
0-1%) did not affect the economics of the ECV decision
so are considered not sensitive factors in the model.
Furthermore, the model was not sensitive to variations
in the cost of ECV (range $950-$1,200).
Discussion
We computed the baseline cost for ECV to be $1,024,
similar to that determined by Gifford et al [31]. From
society’s perspective, a trial of ECV at this general cost
for our base case is cost-effective when compared to a
scheduled cesarean delivery for breech presentation pro-
vided the probability of successful ECV is greater than
32%. Our hypothetical base case (a parturient presenting
with a confirmed singleton breech fetus at ≥ 36 com-
pleted weeks gestation with no contraindications for
Table 3 Estimated Costs (2007 U.S. Dollars) of ECV and Vaginal/Cesarean Delivery
ECV Vaginal Delivery Elective Emergency
Cesarean Delivery Cesarean Delivery
Mean hospital cost $738 $3,605 $5,719 $5,719
Cost of obstetrician’s professional service $195 $1,587 $1,776 $1,792
Cost of anesthesiologist’s service - $198 $228 $486
Cost of Mother’s Time $91 $191 $300 $400
Total $1,024 $5,581 $8,023 $8,397
*Cost of Mother’s time was itemized for each procedure expected duration/expected length of stay




Fetal heart rate monitoring ($53/hr × 1.5 hrs) 79.00
Electrocardiogram 65.00
Ultrasound scan ($86/scan × 2 scans) 172.00
Labor room ($116/hr × 1.5 hrs) 174.00
Blood Tests and drugs 175.00









Cost of obstetrician’s professional service
Physician 114.00
Labor Nurse 81.00
Cost of Mother’s Time 91.00
Total Cost of ECV 1,024.00
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vaginal delivery) is similar to the type of patient the
ACOG recommends for trial of ECV [12,18]. When the
probability of successful ECV is between 32% and 63%,
trial of ECV costs more than cesarean but is still cost-
effective because of the expected improved outcomes
with ECV. This is possible because within this range,
the incremental cost-effectiveness ratio for the ECV
intervention was still less than the cost-effectiveness
threshold of $50,000 per QALY. If the probability of
successful ECV is greater than 63%, it is considered a
dominant decision as a trial of ECV produces better
outcomes and at less cost than a scheduled cesarean.
Although ACOG indicated the average probability of
successful ECV to be 58%, the literature provides a
range of reported success rates [18]. Since the cost-
effectiveness of ECV hinges on the probability of suc-
cessful ECV, results from this study are only as useful as
the ability to determine the chance of a successful ECV
being conducted on a specific patient. Maternal factors
associated with an increased ECV success include higher
parity [32,33], transverse-oblique presentations, posterior
placenta [32], low uterine tone, non-frank breech pre-
sentations [33,34] and non-engagement of the present-
ing part [35]. Conversely, maternal factors associated
with decreased ECV success rates include increased
maternal weight [32] and advanced cervical dilation [36].
Other factors may also contribute to ECV success. A
recent meta-analysis examining sixteen studies deter-
mined that epidural analgesia and tocolysis significantly
improved ECV success rates when compared to controls
[37]. However, the meta-analysis could not provide defi-
nitive evidence of a benefit from the use of spinal
analgesia, vibroacoustic stimulation or transabdominal
amnioinfusion [37]. Despite current knowledge of fac-
tors influencing probability of successful ECV [38], no
single scoring system has been developed that accurately
predicts ECV success [18].
Although several previous studies have assessed the
economics of ECV, investigators did not incorporate
quality of life as outcome measures in their findings
[31,32,39]. Adams et al determined that if ECV was
attempted, ECV saved about $3,000 per delivery [39].
Mauldin et al found that ECV saved $2,462 for each
successful version [32]. Gifford et al assessed the deliv-
ery outcomes and cost of each method of delivery for
breech presentation and determined that routine ECV
practice can result in more vaginal deliveries and lower
costs than strategies that do not include ECV [31].
These studies, however, were published before the
results of the Term Breech Trial and therefore incorpo-
rated the use of assisted vaginal breech delivery in their
management options as an alternative to ECV and
cesarean delivery. Furthermore, the chance of an adverse
outcome due to vaginal breech delivery or emergency
cesarean was not incorporated into these different stu-
dies. Although the risk of adverse events, such as in the
case of emergency cesarean is low, the high cost from a
financial and quality of life standpoint should be incor-
porated into an economic analysis such as the one pre-
sented here. Vaginal breech delivery was not included in
our model because of the demonstrated high risk of the
procedure over cesarean breech delivery and it not
being undertaken in common obstetric practice.
Limitations of this study are similar to those of any
cost-effectiveness analysis. The cost-effectiveness for
ECV as determined in this study is dependent on accu-
rate estimates of probability and costs as factored into
our computer model. To address this, we conducted
sensitivity analyses for all probabilities and costs across
the range of values found in our literature review. We
consider the model robust since the probability of suc-
cessful ECV, as we suspected a priori, was the key vari-
able in the model.
Another limitation of this study was the use of a stan-
dard 6-week and 8-week time horizon for vaginal deliv-
ery or cesarean delivery respectively. This time horizon
accounted for variations in recovery between vaginal
delivery, cesarean delivery and an adverse delivery. How-
ever, this time horizon did not include longer-term
health effects such as costs of future deliveries including
repeated cesarean delivery and vaginal birth after cesar-
ean. While these are important considerations, extend-
ing the time horizon further would significantly increase
the complexity of the model as many other factors
would need to be estimated.
Interestingly, the model was not sensitive to the prob-
ability of conducting a cesarean despite a successful
ECV with no spontaneous reversion. This can be
explained in part because the sum cost of ECV and sub-
sequent vaginal delivery is similar to the cost of con-
ducting a scheduled cesarean. The decision modeling
also revealed that the cost of an adverse outcome asso-
ciated with an emergency cesarean does not greatly
impact the decision, which may be due to extremely low
Table 5 Expected Costs per Strategy Using Baseline Values and Incremental Cost-Effectiveness Ratio
Delivery Strategy Expected Costs ($) Incremental Cost ($) QALY Incremental QALY ICER* ($/QALY)
Schedule Elective Cesarean $8,023 - 0.97 - -
Trial of External Cephalic Version $8,102 $79 0.98 0.01 $7,900.00
*ICER - Incremental Cost-Effectiveness Ratio
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probability of an adverse outcome occurring offsets the
potentially high cost of such an event [21].
This study examined the cost-effectiveness of ECV
from society’s perspective and not for a particular
patient’s preferences for delivery. Patient preferences
should continue to play an important role in the deliv-
ery method for breech presentation. In fact, recent stu-
dies show the majority of women prefer a vaginal birth
over a cesarean delivery, but would choose a cesarean if
medically indicated [40-42]. Educating patients about
potential risks in addition to potential benefits of a trial
of ECV may help patients in their decision to balance
both personal preference and medical needs.
Conclusions
From society’s perspective, ECV trial is cost-effective
when compared to a scheduled cesarean for breech pre-
sentation provided the probability of successful ECV is
> 32%. Improved algorithms incorporating maternal,
clinician and procedure intervention factors should be
developed to determine the probability a patient will
have a successful ECV. Using a reliable and valid scoring
system to predict the chance of ECV success can be
combined with maternal preferences in clinical decision-
making.
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